Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: different gene signatures in M1(Lps+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol 10:1080
Italiani P, Boraschi D (2014) From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 5:514
Wang N, Liang H, Zen K (2014) Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front Immunol 5:614
Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M (2020) The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B 10(11):2156-70
Rhee I (2016) Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res 39(11):1588-96
Tan Y, Wang M, Zhang Y, Ge S, Zhong F, Xia G et al (2021) Tumor-Associated macrophages: a potential target for Cancer Therapy. Front Oncol 11:693517
Feng LL, Cai YQ, Zhu MC, Xing LJ, Wang X (2020) The Yin and Yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 20:1-11
Nuñez-Rios JD, Ulrich H, Díaz-Muñoz M, Lameu C, Vázquez-Cuevas FG (2023) Purinergic system in cancer stem cells. Purinergic Signalling. Springer Science and Business Media B.V.
Jacob F, Novo CP, Bachert C, Van Crombruggen K (2013) Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:285-306
Virgilio F, Di, Sarti AC, Coutinho-Silva R (2020) Purinergic signaling, DAMPs, and inflammation. Am J Physiol Cell Physiol 318(5):C832–C835
Di Virgilio F, Vuerich M (2015) Purinergic signaling in the immune system. Autonomic Neurosci 191:117-23
Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic Signaling during inflammation. N Engl J Med 367(24):2322-2333
Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461(7261):282-6
Adinolfi E, De Marchi E, Orioli E, Pegoraro A, Di Virgilio F (2019) Role of the P2X7 receptor in tumor-associated inflammation. Curr Opin Pharmacol 47:59-64
De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A et al (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38:19
Inoue Y, Chen Y, Hirsh MI, Yip L, Junger WG (2008) A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 30(2):173-177
Antonioli L, Pacher P, Vizi ES, Haskó G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19:355-67
Ohta A (2016) A metabolic immune checkpoint: Adenosine in Tumor Microenvironment. Front Immunol 7:109
Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14(9):1583-9
Pelegrin P, Barroso-Gutierrez C, Surprenant A (2008) P2X7 receptor differentially couples to distinct release pathways for IL-1β in mouse macrophage. J Immunol 180(11):7147-7157
Barberà-Cremades M, Gómez AI, Baroja-Mazo A, Martínez-Alarcón L, Martínez CM, de Torre-Minguela C et al (2017) P2X7 receptor induces tumor necrosis factor-α converting enzyme activation and release to boost TNF-α production. Front Immunol 8:862
Gu BJ, Wiley JS (2006) Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107(12):4946-53
Barberà-Cremades M, Baroja‐Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrín P (2012) P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release. FASEB J 26(7):2951-62
Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 12:76
Qin J, Zhang X, Tan B, Zhang S, Yin C, Xue Q et al (2020) Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res 8(11):1426-39
Wu C, Zhao Y, Xiao X, Fan Y, Kloc M, Liu W et al (2016) Graft-infiltrating macrophages adopt an M2 phenotype and are inhibited by purinergic receptor P2X7 antagonist in chronic rejection. Am J Transplant 16(9):2563-73
Ulrich H, Ratajczak MZ, Schneider G, Adinolfi E, Orioli E, Ferrazoli EG et al (2018) Kinin and purine signaling contributes to neuroblastoma metastasis. Front Pharmacol 9(MAY):500
Arnaud-Sampaio VF, Bento CA, Glaser T, Adinolfi E, Ulrich H, Lameu C (2022) P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma. Front Oncol 12:966404
Zanoni M, Sarti AC, Zamagni A, Cortesi M, Pignatta S, Arienti C et al (2022) Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma. Cell Death Dis 13(1):80
Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E et al (2017) ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front Immunol 8(DEC):1918
Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al (2009) Chemotherapy induces ATP release from tumor cells. Cell Cycle 8(22):3723-8
Virgilio F, Di (1998) Purinergic P2X7 receptor: A pivotal role in inflammation and immunomodulation. Drug Dev Res 45:207–213
De Torre-Minguela C, Barberà-Cremades M, Gómez AI, Martín-Sánchez F, Pelegrín P (2016) Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci Rep 6:22586
Pegoraro A, Orioli E, De Marchi E, Salvestrini V, Milani A, Di Virgilio F et al (2020) Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression. Cell Death Dis 11(10):876
Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV (2018) Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res 2018:7394268. Hindawi Limited
Park JR, Eggert A, Caron H, Neuroblastoma (2010) Biology, Prognosis, and treatment. Hematol/Oncol Clin N Am 24(1):65-86
Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P et al (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72(12):2957–2969
Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P et al (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24(9):3393-404
Weischenfeldt J, Porse B (2008) Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. pdb.prot5080
Zhang X, Goncalves R, Mosser DM (2008) The isolation and characterization of murine macrophages. Curr Protocols Immunol 83(1):14
Lameu C, Pontieri V, Guerreiro JR, Oliveira EF, Da Silva CA, Giglio JM et al (2010) Brain nitric oxide production by a proline-rich decapeptide from Bothrops jararaca venom improves baroreflex sensitivity of spontaneously hypertensive rats. Hypertens Res 33(12):1283-8
Arnaud-Sampaio VF, Rabelo ILA, Bento CA, Glaser T, Bezerra J, Coutinho-Silva R et al (2020) Using cytometry for investigation of Purinergic Signaling in Tumor-Associated macrophages. Cytometry Part A 97(11):1109-26
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L et al (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078
Zhu J, Wang J, Sun F, Zhen Z, Chen T, Lu S et al (2022) Vincristine, Irinotecan, and Temozolomide in patients with Relapsed/Refractory neuroblastoma. Front Oncol 12:804310
Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J et al (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104(1):36-43
Jemaà M, Sime W, Abassi Y, Lasorsa VA, Køhler JB, Michaelis M et al (2020) Gene expression signature of acquired chemoresistance in neuroblastoma cells. Int J Mol Sci 21(18):6811
Cho YK, Son Y, Kim SN, Song HD, Kim M, Park JH et al (2019) MicroRNA-10a-5p regulates macrophage polarization and promotes therapeutic adipose tissue remodeling. Mol Metab 29:86-98
Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of Gene expression. J Immunol 177(10):7303-7311
Shen W, Wang S, Wang R, Zhang Y, Tian H, Yang X et al (2021) Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures. Ann Transl Med 9(16):1333
Ribeiro ARB, Silva ECO, Araújo PMC, Souza ST, Fonseca EJ da S, Barreto E (2022) Application of Raman spectroscopy for characterization of the functional polarization of macrophages into M1 and M2 cells. Spectrochim Acta Mol Biomol Spectrosc 265:120328
Lee C, Jeong H, Bae Y, Shin K, Kang S, Kim H et al (2019) Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer 7(1):147
Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L et al (2024) Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 8(1):31
El-Brolosy MA, Stainier DYR (2017) Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet 13:e1006780. Public Library of Science
El-Brolosy MA, Kontarakis Z, Rossi A, Kuenne C, Günther S, Fukuda N et al (2019) Genetic compensation triggered by mutant mRNA degradation. Nature 568(7751):193–197
Article PubMed PubMed Central Google Scholar
Murphy PS, Wang J, Bhagwat SP, Munger JC, Janssen WJ, Wright TW et al (2017) CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages. Cell Death Differ 24(3):559–570
Article PubMed PubMed Central Google Scholar
Kreckler LM, Wan TC, Ge ZD, Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-α release from mouse peritoneal macrophages via A2A and A2B but not the A 3 adenosine receptor. J Pharmacol Exp Ther 317(1):172-80
D’Alterio C, Scala S, Sozzi G, Roz L, Bertolini G (2020) Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion, vol 60. Seminars in Cancer Biology. Academic Press
Arlauckas SP, Garren SB, Garris CS, Kohler RH, Oh J, Pittet MJ et al (2018) Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics 8(21):5842–5854
Article PubMed PubMed Central Google Scholar
de la Rosa G, Gómez AI, Baños MC, Pelegrín P (2020) Signaling through purinergic receptor p2y2 enhances macrophage il-1β production. Int J Mol Sci 21(13):1–17
Thorstenberg ML, Ferreira MVR, Amorim N, Canetti C, Morrone FB, Filho JCA et al (2018) Purinergic cooperation between P2Y2 and P2X7 receptors promote cutaneous leishmaniasis control: Involvement of pannexin-1 and leukotrienes. Front Immunol 9(JUL):1531
Csoka B, Selmeczy Z, Koscso B, Nemeth ZH, Pacher P, Murray PJ et al (2012) Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 26:376
Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-Mesenchymal Transitions in Development and Disease. Cell 139:871-90
Di Virgilio F (1995) The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today 16(11):524-528
Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK et al (2023) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10:1367-1401
Abdullah LN, Chow EKH (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2:1–9
Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M, Kzhyshkowska J (2019) Interaction of tumor-associated macrophages and cancer chemotherapy. OncoImmunology 8:e1596004
Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F et al (2014) Trophic activity of human P2X7 receptor isoforms a and B in osteosarcoma. PLoS ONE 9(9):e107224
Park JH, Kim YC (2017) P2X7 receptor antagonists: a patent review (2010–2015). Expert Opin Ther Patents 27(3):257-67
DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369-82
留言 (0)